Sameek Roychowdhury, MD, PhD
College of Medicine
Cancer, Graft vs Host Disease, Lymphoproliferative Disorders, Prostatic Cancer, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Solitary Fibrous Tumors, Lymphoma, Breast Cancer, Burkitt Lymphoma, Hemangiopericytoma
Sameek Roychowdhury, MD, PhD, is a member of the Translational Therapeutics Program at OSUCCC – James, where he is working to identify putative predictive genomic biomarkers for targeted therapies and to understand resistance mechanisms for those therapies.
His research involves translating next-generation DNA-sequencing strategies for genomics-driven clinical trials. In particular, he is working with advanced-cancer patients considering clinical trials to identify driving mutations that match novel molecularly targeted therapies in development.
In a recent research project, he provided guidance and consideration points to laboratories and clinicians on the potential for germline findings in tumor sequencing.
Dr. Roychowdhury has co-authored more than a dozen articles in well-respected publications, including Journal of the American Medical Association, Journal of the National Cancer Institute, Human Mutation and Journal of Clinical Oncology.